retatrutide sequence retatrutide - Retatrutidecas Number Retatrutide sequence Unraveling the Retatrutide Sequence: A Deep Dive into a Novel Triple Agonist

Retatrutidecas Number The retatrutide sequence represents a significant advancement in the development of therapeutic peptides, particularly for metabolic disorders. This complex molecule, also identified by its CAS number 2381089-83-2, is a synthetic peptide with a remarkable structure and a tripartite mechanism of action. Understanding its retatrutidechemical sequence is crucial for appreciating its biological activity and potential pharmaceutical applications.[β-Asp]15-Retatrutide

At its core, retatrutide is an oligopeptide, a chain of amino acids. Various sources provide slightly different representations of this retatrutidepeptide sequence, often due to variations in notation for non-standard amino acids and specific modifications. However, a widely accepted depiction of the amino acid sequence is YA¹QGTFTSDYSL²LDKKAQA¹AFIEYLLEGGPSSGAPPPS³. Another detailed representation is YXQGTFTSDY SILLDKKAQX AFIEYLLEGG PSSGAPPPS. The retatrutidechemical name itself hints at its complexity, and the retatrutidepeptide structure allows it to interact with multiple hormone receptors.

The retatrutide (LY3437943) molecule is characterized by not only its primary amino acid arrangement but also by the inclusion of non-coded amino acid residues. These modifications are key to its enhanced stability and efficacy. Specifically, the retatrutide sequence incorporates non-natural amino acids at specific positions, such as Aib², Aib²⁰, and aMeL¹³2024年8月7日—Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested byretatrutide. ;SequenceAnnotations. Expand.. These modified residues contribute to increased stability and are detailed in discussions about retatrutide synthesis. Furthermore, the peptide backbone sequence of Retatrutide contains three non-code amino acid residues at positions 2, 20, and 13, enhancing its overall robustness.

Beyond the amino acid chain, retatrutide is further modified with a C20 fatty diacid moietySynthesis of retatrutide by native chemical ligation (NCL), a .... This lipidation is a critical design element, enabling albumin binding.RETATRUTIDE [USAN]. Common Name, English ;L-Tyrosyl-2-methylalanyl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-?-aspartyl-L-tyrosyl-L- ... This binding prolongs the drug's half-life in the body, leading to less frequent dosing and improved patient compliance. The retatrutide chemical structure therefore comprises both the peptide sequence and this essential fatty acid appendage, collectively contributing to its pharmacokinetic profile. Information on the retatrutide molecular weight places it at approximately 4731 g/mol or 4731.34, reflecting the substantial size of this complex molecule. Its exact mass is reported as 4728.4718Chemistry. edit.Retatrutideis a peptide with the following amino acidsequence. YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³. where letters with ....

The functional significance of the retatrutide sequence lies in its action as a triple agonist.Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide derived from a GIP backbone, featuring non-coded residues (Aib2, Aib20, aMeL13) and a C20 fatty ... It targets three key receptors: the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R).Compound: RETATRUTIDE (CHEMBL5095485) - ChEMBL This simultaneous activation of multiple pathways is a novel approach to managing complex metabolic conditions.Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide derived from a GIP backbone, featuring non-coded residues (Aib2, Aib20, aMeL13) and a C20 fatty ... The triple agonist activity is a cornerstone of retatrutide's mechanism of action, differentiating it from earlier single or dual agonists like semaglutide. Research into the retatrutide (LY3437943) TFA form, as well as understanding retatrutide (LY3437943), provides further insight into its therapeutic potential.

The retatrutide sequence and its modifications are the subject of extensive research and development, including detailed studies on retatrutide synthesis. Various synthetic methodologies are being explored, such as native chemical ligation (NCL), to efficiently produce this complex peptide. Innovations in retatrutide synthesis ensure high purity, with reported purities of 99.Retatrutide | C221H342N46O68 | CID 171390338 - PubChem4% peptide. The development of this peptide involves intricate chemical processes to assemble the retatrutide sequence with the required precision.

While specific details on every amino acid might vary slightly in publicly available datasheets, the core retatrutide sequence and its key structural features are well-established. For instance, the peptide backbone sequence of Retatrutide contains three non-code amino acid residues at positions 2, 20, and 13. Such modifications, like the [β-Asp]¹⁵-Retatrutide variant, highlight the ongoing efforts to fine-tune the molecule. The therapeutic target of retatrutide is critically linked to the GIPR and GCGR receptors, along with GLP-1RWhat is the mechanism of action of retatrutide? - Lilly Medical. The drug's efficacy is a direct consequence of its precisely engineered sequence.

In summary, the retatrutide sequence, represented by its complex arrangement of amino acids and strategic non-coded residues, along with its fatty acid modification, underpins its role as a potent triple agonist. This meticulous design allows retatrutide to target GCGR, GIPR, and GLP-1R receptors, offering a promising new avenue for therapeutic intervention in metabolic diseasesTriple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 .... Analytical data, such as its retatrutidemolecular weight, and its detailed exploration in scientific literature solidify its position as a leading candidate in pharmaceutical research, with ongoing investigations into its retatrutide chemical structure and various synthetic pathways.